Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-01, Stock:ABBV, The news for the past five days is as follows:
2019-01-25: NEWS1: Why Intel, AbbVie, and Vale Slumped Today.NEWS2: Why Intel, AbbVie, and Vale Slumped Today.NEWS3: Western Digital, Starbucks rise while AbbVie, Intel drop.NEWS4: AbbVie Earnings: ABBV Stock Falters on Q4 Miss.NEWS5: AbbVie Earnings: ABBV Stock Falters on Q4 Miss.NEWS6: Why Intel, AbbVie, and Vale Slumped Today.NEWS7: AbbVie Stock Crumbles After Biosimilars Take A Chunk Of Humira Sales.NEWS8: AbbVie Falls After Missing Top- and Bottom-Line Estimates.NEWS9: Health Care Sector Update for 01/25/2019: CHRS,AMGN,RMD,AZN,IDXG,ABBV.NEWS10: Health Care Sector Update for 01/25/2019: CHRS,AMGN,RMD,AZN,IDXG,ABBV.NEWS11: AbbVie Q4 Earnings: 3 Key Things You Need to Know.NEWS12: AbbVie Q4 Earnings: 3 Key Things You Need to Know.NEWS13: AbbVie Inc (ABBV) Q4 2018 Earnings Conference Call Transcript.NEWS14: AbbVie Inc (ABBV) Q4 2018 Earnings Conference Call Transcript.NEWS15: AbbVie Inc (ABBV) Q4 2018 Earnings Conference Call Transcript.NEWS16: Health Care Sector Update for 01/25/2019: AZN,IDXG,ABBV.NEWS17: Health Care Sector Update for 01/25/2019: AZN,IDXG,ABBV.NEWS18: AbbVie Q4 Earnings: 3 Key Things You Need to Know.NEWS19: Congressional Activities on Shutdown in Focus.NEWS20: Congressional Activities on Shutdown in Focus.NEWS21: Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV.NEWS22: Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV.NEWS23: Asia, Congress Activity, Put Futures in the Green.NEWS24: Asia, Congress Activity, Put Futures in the Green.NEWS25: AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down.NEWS26: AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down.NEWS27: Celgene Stock Is Rising After the CEO of AbbVie Ruled Out a Big Deal.NEWS28: AbbVie (ABBV) Misses Q4 Earnings and Revenues, Shares Down.NEWS29: AbbVie (ABBV) Misses Q4 Earnings and Revenues, Shares Down.NEWS30: Celgene Shares Rise as AbbVie CEO Rules Out Big Deal.NEWS31: [$$] Drug Maker AbbVie Swings to Loss on Charge from Stemcentrx Deal.NEWS32: AbbVie Earnings: ABBV Stock Falters on Q4 Miss.NEWS33: AbbVie expects steeper decline in Humira's overseas sales; shares fall.NEWS34: Congressional Activities on Shutdown in Focus.NEWS35: AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down.NEWS36: Asia, Congress Activity, Put Futures in the Green.NEWS37: Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV.NEWS38: Wall Street's Risk Appetite Improves on Upcoming Trade Talks, Tech Sector Gains.NEWS39: Wall Street's Risk Appetite Improves on Upcoming Trade Talks, Tech Sector Gains.NEWS40: AbbVie not contemplating big deals - CEO.NEWS41: Health Care Sector Update for 01/25/2019: IDXG, RMD, ABBV, JNJ, PFE, MRK, ABT, AMGN.NEWS42: Health Care Sector Update for 01/25/2019: IDXG, RMD, ABBV, JNJ, PFE, MRK, ABT, AMGN.NEWS43: US STOCKS-Wall St set to open higher as investors focus on upbeat earnings.NEWS44: AbbVie (ABBV) Misses Q4 Earnings and Revenues, Shares Down.NEWS45: AbbVie (ABBV) Lags Q4 Earnings and Revenue Estimates.NEWS46: AbbVie Falls 6%.NEWS47: AbbVie: 4Q Earnings Snapshot.NEWS48: AbbVie Earnings, Revenue Fall Short As Humira Sales Dive Overseas.NEWS49: Abbvie shares slide 2.3% premarket after earnings miss.NEWS50: AbbVie profit misses as Humira faces biosimilar challenge in Europe.NEWS51: AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results.NEWS52: Earnings Reaction History: AbbVie Inc., 58.3% Follow-Through Indicator, 3.7% Sensitive.NEWS53: Earnings Reaction History: AbbVie Inc., 58.3% Follow-Through Indicator, 3.7% Sensitive.NEWS54: Top Picks 2019- AbbVie ABBV.NEWS55: Coherus Reaches Settlement With AbbVie Securing Rights To Commercialize CHS-1420.NEWS56: Coherus Reaches Settlement With AbbVie Securing Rights To Commercialize CHS-1420.NEWS57: AbbVie Q4 Results Miss View; Stock Down.NEWS58: AbbVie Q4 Results Miss View; Stock Down.NEWS59: AbbVie Earnings, Revenue miss in Q4.NEWS60: Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?.NEWS61: Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?.NEWS62: Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?.
2019-01-28: NEWS1: AbbVie Missed Revenue Estimates in Q4 2018.NEWS2: Health Care Sector Update for 01/28/2019: ABBV,ALXN,TRVN,ARAY.NEWS3: Health Care Sector Update for 01/28/2019: ABBV,ALXN,TRVN,ARAY.NEWS4: What Are Analysts Recommending for AbbVie after Q4 2018 Results?.NEWS5: Monday Sector Laggards: Energy, Healthcare.NEWS6: Monday Sector Laggards: Energy, Healthcare.NEWS7: Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN.NEWS8: Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN.NEWS9: Is AbbVie in Hot Water?.NEWS10: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS11: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS12: The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck.NEWS13: The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck.NEWS14: Analysts Cut AbbVie Price Targets After Earnings Miss.NEWS15: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS16: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS17: Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN.NEWS18: The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck.NEWS19: Health Care Sector Update for 01/28/2019: TRVN, ARAY, ABBV, JNJ, PFE, ABT, MRK, AMGN.NEWS20: Health Care Sector Update for 01/28/2019: TRVN, ARAY, ABBV, JNJ, PFE, ABT, MRK, AMGN.NEWS21: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS22: AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients.NEWS23: AbbVie Falls 3%.NEWS24: What's Making News In These Pharma And Cannabis Stocks Today?.NEWS25: What's Making News In These Pharma And Cannabis Stocks Today?.NEWS26: 3 Reasons AbbVie Investors Aren't Too Worried About Humira Anymore.NEWS27: 3 Reasons AbbVie Investors Aren't Too Worried About Humira Anymore.NEWS28: 3 Reasons AbbVie Investors Aren&apos;t Too Worried About Humira Anymore.
2019-01-29: NEWS1: Cramer's lightning round: AbbVie needs to make an acquisition—it might just save its stock.NEWS2: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS3: 10 Value Stocks to Buy for 2019 and Beyond.NEWS4: Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y.NEWS5: Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y.NEWS6: Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y.NEWS7: AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting.NEWS8: AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting.NEWS9: 3 Top Dividend Stocks to Buy Right Now.NEWS10: 3 Top Dividend Stocks to Buy Right Now.NEWS11: Jacksonville's increasing use of LNG as a transportation fuel.NEWS12: Imbruvica Is Key Growth Driver for AbbVie in Fiscal 2019.NEWS13: 3 Top Dividend Stocks to Buy Right Now.NEWS14: Health Care Sector Update for 01/29/2019: ARAY, TRVN, ABBV, JNJ, PFE, ABT, MRK, AMGN.NEWS15: Health Care Sector Update for 01/29/2019: ARAY, TRVN, ABBV, JNJ, PFE, ABT, MRK, AMGN.NEWS16: AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting.NEWS17: Why Humira Revenues in International Markets Are Expected to Fall.NEWS18: AbbVie Missed EPS Estimates in Q4 2018.NEWS19: The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive.
2019-01-30: NEWS1: 10 Value Stocks to Buy for 2019 and Beyond.NEWS2: 10 Value Stocks to Buy for 2019 and Beyond.NEWS3: ABBV Stock Is Worth a Look at Multi-Year Lows.NEWS4: ABBV Stock Is Worth a Look at Multi-Year Lows.NEWS5: 3 Big Pharmas Expecting a Softer 2019.NEWS6: 3 Big Pharmas Expecting a Softer 2019.NEWS7: ABBV Stock Is Worth a Look at Multi-Year Lows.NEWS8: Genentech kills big drug study in early Alzheimer's patients.NEWS9: AbbVie Reports Improvement in Margins in Fiscal 2018.NEWS10: 3 Big Pharmas Expecting a Softer 2019.NEWS11: A Look at AbbVie’s Diversified Product Portfolio in Fiscal 2019.NEWS12: Jim Cramer Gives His Opinion On AbbVie, Idexx Labs And More.NEWS13: Edited Transcript of ABBV earnings conference call or presentation 25-Jan-19 2:00pm GMT.NEWS14: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS15: AbbVie (ABBV) Gains As Market Dips: What You Should Know.
2019-01-31: NEWS1: Top Research Reports for Union Pacific, AbbVie & General Dynamics.NEWS2: 3 Top Large-Cap Stocks to Buy in February.NEWS3: 3 Top Large-Cap Stocks to Buy in February.

Answer: Rise